Navigation Links
Watson Enters Into Agreement to Acquire Products Related to Teva's Proposed Acquisition of Barr
Date:11/25/2008

CORONA, Calif., Nov. 25 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today announced a definitive agreement to acquire a portfolio of generic pharmaceutical products that are being divested as a result of the proposed merger between Teva Pharmaceutical Industries, Ltd. and Barr Pharmaceuticals, Inc. The closing of the product acquisition is contingent upon the consummation of Teva's merger with Barr.

The portfolio of products consists of 17 products, including 15 FDA-approved products and 2 development-stage products. Key products in the portfolio include:

        Cyclosporine Capsules and Liquid
        Desmopressin Acetate Tablets
        Glipizide/Metformin HCl Tablets
        Mirtazapine Orally Disintegrating Tablets
        Metoclopramide HCl Tablets

"These products represent a sound complement to our extensive generics portfolio," said Paul Bisaro, President and Chief Executive Officer of Watson. He added, "We anticipate these new generics will have immediate value that we will begin to realize in early 2009."

Under the terms of the agreement, Watson will acquire the portfolio of products for an upfront payment of $36 million and will make additional payments to Teva when certain milestones are met on the development-stage products. Teva will supply the products to Watson under a Manufacturing and Supply Agreement until manufacturing is transferred to Watson or a third party.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc., headquartered in Corona, CA, is a leading specialty pharmaceutical company that develops, manufactures, markets, sells and distributes generic and specialty brand pharmaceutical products. Watson pursues a growth strategy combining internal product development, strategic alliances and collaborations and synergistic acquisitions of products and businesses.

For press releases and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement

Any statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Watson's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, the difficulty of predicting the timing of the consummation of the merger between Teva Pharmaceutical Industries, Ltd. and Barr Pharmaceuticals, Inc.,; potential delays caused by the need to obtain regulatory approvals and actions, including the requirement for the Federal Trade Commission to approve the merger between Teva and Barr and the sale of the subject products to Watson Laboratories, Inc.; the impact of competitive products and pricing; market acceptance of and continued demand for Watson's products; difficulties or delays in manufacturing; the difficulty of predicting the timing or outcome of FDA or other regulatory agency approvals or actions, if any; patents and other intellectual property rights of third parties and the uncertainty of the outcome of any litigation related to such patents or intellectual property rights; and other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's Annual Report on Form 10-K for the year ended December 31, 2007.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO)


'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
2. Watson Wyatt Identifies Major Benefit Trends During Open Enrollment Season
3. Texas Affiliates of Susan G. Komen for the Cure, Sen. Kirk Watson, Rep. Patrick Rose, Singer Kelly Willis, Breast Cancer Survivors and Activists Rally for Passage of Proposition 15
4. Watson Files FDA Application for Generic YAZ(R)
5. Watson Names Mark Durand Chief Financial Officer
6. Watson and Novartis Settle Lawsuit Over Exelon(R) Patent Litigation
7. Barr Subsidiary Sues Watson and Sandoz for SEASONALE(R) Patent Infringement
8. Watson Confirms Patent Litigation With Barr Related to Seasonale(R)
9. Watson Receives FDA Approval for Generic DuoNeb(R)
10. Watson to Distribute Alendronate Tablets
11. Medical Cost Increases to Accelerate Worldwide Over Next Five Years, Watson Wyatt Poll Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2017)... ... June 28, 2017 , ... ... and the surrounding regions access to insurance assistance and financial planning services, is ... Ministries to assist families in the region facing financial crisis. , Matthew 25: ...
(Date:6/27/2017)... IL (PRWEB) , ... June 27, 2017 , ... ... considering a cosmetic treatment, according to survey data released today by the ... on Cosmetic Dermatologic Procedures indicates the percentage of consumers considering a cosmetic ...
(Date:6/27/2017)... ... June 27, 2017 , ... The Congressional Budget Office ... repeal and replace the 2010 Patient Protection and Affordable Care Act (ACA), would result ... would be expected under current law. , More than 20 million Americans have gained ...
(Date:6/27/2017)... ... , ... Two residents from the Gardant-managed assisted living and memory care communities ... lawmakers to protect Medicaid funding. , The video, which was produced by the American ... Chuck and Cathy Schwarz, a couple who is still able to see each other ...
(Date:6/27/2017)... ... June 27, 2017 , ... Drs. Gregory Toback and Marianne ... Mystic, CT. Covering the process and maintenance strategies of gum grafting and dental ... procedures. Drs. Toback and Urbanski practice as experienced periodontists in New ...
Breaking Medicine News(10 mins):
(Date:6/5/2017)... OMAHA, Neb. , June 5, 2017 /PRNewswire/ ... chair in the United States ... chair that helps a fallen person up to an ... is easily assembled and operated by one assistant and ... hand. It is simple enough that a child can ...
(Date:6/1/2017)... Pa. , June 1, 2017 Nutriceutical ... and Veterinarian Recommended Solutions (VRS), and KD Pharma Group ... in Nutriceutical Holdings by KD Pharma Group. KD Pharma ... with the option to acquire the entire company. ... in KD. They are committed to growing the NH ...
(Date:5/30/2017)... Israel , May 30, 2017 Therapix ... pharmaceutical Company specializing in the development of cannabinoid-based ... present a company overview at three upcoming scientific ... 7th Annual LD Micro Invitational: ... Date:                     ...
Breaking Medicine Technology: